UNICREDIT BANK/CALL/ASTRAZENECA/13500/0.1/18.12.24 | Real-time BOERSE MUENCHEN 01:16:16 24/05/2024 am IST | ||
| 0.64 EUR | +3.23% |
|
| Current month | +12.73% | ||
| 1 month | +82.35% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ASTRAZENECA PLC
Latest news about ASTRAZENECA PLC
More news
| Date | Price | Change |
|---|---|---|
| 24/24/24 | 0.64 | +3.23% |
| 22/24/22 | 0.62 | -3.13% |
| 21/24/21 | 0.64 | +23.08% |
| 20/24/20 | 0.52 | -3.70% |
| 17/24/17 | 0.54 | -3.57% |
Real-time BOERSE MUENCHEN
Last update May 24, 2024 at 01:16 am IST
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ASTRAZENECA PLC |
| Issuer | 
UniCredit
|
| WKN | HD4FHC |
| ISIN | DE000HD4FHC9 |
| Date issued | 08/04/2024 |
| Strike | 13,500 p |
| Maturity | 18/12/2024 (209 Days) |
| Parity | 10 : 1 |
| Emission price | 0.21 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 0.71 € |
|---|---|
| Lowest since issue | 0.19 € |
| Spread | 0.03 € |
| Spread % | 4.69% |
Company Profile
AstraZeneca PLC is one of the world's leading pharmaceutical groups. Net sales break down by source of income as follows:
- product sales (95.6%). Net sales break down by treatment area between oncology (39.2%), cardiovascular, renal and metabolic diseases (24.2%), respiratory and autoimmune diseases (13.9%), and other (22.7%; inflammatory diseases, neurological diseases, gastrointestinal and infectious diseases);
- collaboration revenue (4.4%).
Net sales are distributed geographically as follows: the United Kingdom (7.4%), Europe (21.2%), America (45.3%) and Africa-Asia-Australia (26.1%).
Sector
-
Consensus: AstraZeneca PLC
Sell
Buy
Mean consensus
BUY
Number of Analysts
23
Last Close Price
157.7
USD
Average target price
169.7
USD
Spread / Average Target
+7.62%
- Stock Market
- Warrants
- Warrant
